Apyx Medical Corp. Files 8-K
Ticker: APYX · Form: 8-K · Filed: Jan 6, 2025 · CIK: 719135
| Field | Detail |
|---|---|
| Company | Apyx Medical Corp (APYX) |
| Form Type | 8-K |
| Filed Date | Jan 6, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, procedural, SEC filing
TL;DR
Apyx Medical filed an 8-K, no new info, just procedural.
AI Summary
Apyx Medical Corp. filed an 8-K on January 6, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific details about new events, financial figures, or material changes, but rather serves as a procedural filing.
Why It Matters
This 8-K filing indicates that Apyx Medical Corp. is fulfilling its reporting obligations with the SEC, though it does not disclose new material information.
Risk Assessment
Risk Level: low — The filing is a routine procedural document and does not contain any new material information that would impact the company's risk profile.
Key Players & Entities
- Apyx Medical Corp. (company) — Registrant
- January 6, 2025 (date) — Filing Date
- Delaware (jurisdiction) — State of Incorporation
- Clearwater, Florida (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Apyx Medical Corp.?
The filing is for "Other Events" and "Financial Statements and Exhibits," indicating a procedural reporting requirement rather than the disclosure of new material events.
When was this 8-K filed by Apyx Medical Corp.?
The 8-K was filed on January 6, 2025.
What is the principal executive office address for Apyx Medical Corp.?
The principal executive offices are located at 5115 Ulmerton Road, Clearwater, Florida 33760.
What is the state of incorporation for Apyx Medical Corp.?
Apyx Medical Corp. is incorporated in Delaware.
Does this filing disclose any specific new business developments or financial results?
No, this filing does not appear to disclose specific new business developments or financial results, functioning primarily as a procedural update.
Filing Stats: 424 words · 2 min read · ~1 pages · Grade level 10.8 · Accepted 2025-01-06 08:00:08
Filing Documents
- apyx20250103c_8k.htm (8-K) — 24KB
- ex_762281.htm (EX-99.1) — 14KB
- apyx20240909_8kimg001.jpg (GRAPHIC) — 7KB
- logo.jpg (GRAPHIC) — 8KB
- 0001437749-25-000375.txt ( ) — 196KB
- apyx-20250106.xsd (EX-101.SCH) — 3KB
- apyx-20250106_def.xml (EX-101.DEF) — 11KB
- apyx-20250106_lab.xml (EX-101.LAB) — 15KB
- apyx-20250106_pre.xml (EX-101.PRE) — 11KB
- apyx20250103c_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events On January 6, 2025, Apyx Medical Corporation (the "Company") issued a press release announcing it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration for the AYON Body Contouring System. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 99.1 Press release dated January 6, 2025
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 6, 2025 Apyx Medical Corporation By: /s/ Matthew Hill Matthew Hill Chief Financial Officer, Secretary and Treasurer